newsfilter
← Latest News
GlobeNewswire·

Unicycive Therapeutics to Participate in Upcoming Investor Events in December

  • Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced that CEO Shalabh Gupta, M.D. will participate in two investor events in December.
  • The first event is a Fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3, 2025, at 10:00 a.m. ET.
  • The second event is a Virtual Presentation at Noble Capital Markets on Wednesday, December 10, 2025, at 10:00 a.m. PT.
  • Live \& archived webcasts for both events are available on the Unicycive website under the Investors section.
  • Unicycive is developing oxylanthanum carbonate, a phosphate binding agent currently under FDA review for hyperphosphatemia in dialysis patients with chronic kidney disease.
  • The company's second investigational treatment, UNI-494, targets acute kidney injury conditions \& received FDA orphan drug designation for preventing Delayed Graft Function in kidney transplant patients.
  • UNI-494 has completed a Phase 1 dose-ranging safety study in healthy volunteers.